Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

Filing supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach SEATTLE, WA / ACCESS Newswire / July 27, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a …